Congress Wealth Management LLC DE Has $8.99 Million Holdings in Pfizer Inc. (NYSE:PFE)

Congress Wealth Management LLC DE lessened its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 24.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 338,742 shares of the biopharmaceutical company's stock after selling 112,434 shares during the period. Congress Wealth Management LLC DE's holdings in Pfizer were worth $8,987,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. United Bank boosted its stake in Pfizer by 3.7% in the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company's stock worth $1,030,000 after purchasing an additional 1,277 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Pfizer by 67.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,801 shares of the biopharmaceutical company's stock worth $428,000 after buying an additional 5,959 shares during the period. Larson Financial Group LLC grew its holdings in shares of Pfizer by 50.2% during the third quarter. Larson Financial Group LLC now owns 89,289 shares of the biopharmaceutical company's stock valued at $2,584,000 after buying an additional 29,862 shares in the last quarter. Centaurus Financial Inc. raised its position in Pfizer by 3.4% during the third quarter. Centaurus Financial Inc. now owns 64,543 shares of the biopharmaceutical company's stock valued at $1,868,000 after buying an additional 2,130 shares during the period. Finally, Westfield Capital Management Co. LP lifted its stake in Pfizer by 21.9% in the 3rd quarter. Westfield Capital Management Co. LP now owns 335,556 shares of the biopharmaceutical company's stock worth $9,711,000 after acquiring an additional 60,378 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group decreased their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. Truist Financial cut their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Bank of America restated a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Citigroup cut their price target on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Stock Down 0.1 %

Shares of NYSE:PFE traded down $0.03 during trading on Friday, hitting $24.99. 6,957,055 shares of the company were exchanged, compared to its average volume of 44,710,637. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $141.70 billion, a price-to-earnings ratio of 17.71, a P/E/G ratio of 0.64 and a beta of 0.61. The firm has a fifty day moving average price of $26.09 and a two-hundred day moving average price of $26.97.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's revenue was up 24.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.10 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.06% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.